ADAR1 Capital Management LLC Lowers Holdings in Organon & Co. $OGN

Key Points

• ADAR1 Capital Management LLC significantly reduced its holdings in Organon & Co. by 75.1%, owning only 10,000 shares now, after selling 30,200 shares during the first quarter.
• During the same period, several institutional investors, including Royal Bank of Canada and Jump Financial LLC, increased their stakes in Organon, highlighting a mixed investment climate.
• Analysts currently rate Organon with a consensus of "Moderate Buy" and an average target price of $18.00, despite a 0.2% decline in stock value reported recently.

ADAR1 Capital Management LLC cut its position in shares of Organon & Co. (NYSE:OGN - Free Report) by 75.1% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 10,000 shares of the company's stock after selling 30,200 shares during the quarter. ADAR1 Capital Management LLC's holdings in Organon & Co. were worth $149,000 as of its most recent SEC filing.

Several other institutional investors have also recently modified their holdings of the company. Royal Bank of Canada increased its position in shares of Organon & Co. by 53.4% during the 1st quarter. Royal Bank of Canada now owns 360,862 shares of the company's stock valued at $5,374,000 after purchasing an additional 125,648 shares during the last quarter. State of Wyoming boosted its holdings in Organon & Co. by 23.0% during the 1st quarter. State of Wyoming now owns 22,269 shares of the company's stock valued at $332,000 after acquiring an additional 4,163 shares during the period. Jump Financial LLC boosted its holdings in Organon & Co. by 72.7% during the 1st quarter. Jump Financial LLC now owns 24,702 shares of the company's stock valued at $368,000 after acquiring an additional 10,402 shares during the period. Compound Planning Inc. boosted its holdings in Organon & Co. by 21.9% during the 1st quarter. Compound Planning Inc. now owns 48,383 shares of the company's stock valued at $720,000 after acquiring an additional 8,685 shares during the period. Finally, Dorsey & Whitney Trust CO LLC boosted its holdings in Organon & Co. by 20.4% during the 1st quarter. Dorsey & Whitney Trust CO LLC now owns 19,017 shares of the company's stock valued at $283,000 after acquiring an additional 3,221 shares during the period. 77.43% of the stock is currently owned by institutional investors.

Organon & Co. Stock Up 7.1%

Shares of OGN traded up $0.69 on Friday, reaching $10.37. The stock had a trading volume of 4,651,315 shares, compared to its average volume of 3,674,159. The firm has a market capitalization of $2.69 billion, a price-to-earnings ratio of 3.85, a price-to-earnings-growth ratio of 0.95 and a beta of 0.60. The company has a debt-to-equity ratio of 11.98, a quick ratio of 1.13 and a current ratio of 1.65. The company has a 50-day simple moving average of $9.59 and a 200-day simple moving average of $11.03. Organon & Co. has a 12-month low of $8.01 and a 12-month high of $21.25.

Organon & Co. (NYSE:OGN - Get Free Report) last posted its quarterly earnings data on Tuesday, August 5th. The company reported $1.00 earnings per share for the quarter, beating analysts' consensus estimates of $0.94 by $0.06. The company had revenue of $1.59 billion during the quarter, compared to analyst estimates of $1.55 billion. Organon & Co. had a return on equity of 163.88% and a net margin of 11.15%.The firm's revenue for the quarter was down .8% on a year-over-year basis. During the same quarter last year, the company earned $1.12 EPS. Organon & Co. has set its FY 2025 guidance at EPS. Sell-side analysts predict that Organon & Co. will post 3.68 EPS for the current year.

Organon & Co. Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, September 11th. Shareholders of record on Friday, August 15th will be issued a $0.02 dividend. The ex-dividend date of this dividend is Friday, August 15th. This represents a $0.08 dividend on an annualized basis and a dividend yield of 0.8%. Organon & Co.'s dividend payout ratio (DPR) is presently 2.97%.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on OGN. BNP Paribas upgraded Organon & Co. to a "strong-buy" rating in a report on Thursday, May 22nd. Piper Sandler dropped their target price on Organon & Co. from $24.00 to $18.00 and set an "overweight" rating for the company in a report on Thursday, May 15th. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and two have issued a Hold rating to the company's stock. Based on data from MarketBeat, Organon & Co. currently has a consensus rating of "Moderate Buy" and an average target price of $17.33.

Organon & Co. Profile

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women's health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.